全文获取类型
收费全文 | 275158篇 |
免费 | 22415篇 |
国内免费 | 10988篇 |
专业分类
耳鼻咽喉 | 3753篇 |
儿科学 | 5752篇 |
妇产科学 | 5306篇 |
基础医学 | 30245篇 |
口腔科学 | 3894篇 |
临床医学 | 24778篇 |
内科学 | 30697篇 |
皮肤病学 | 3078篇 |
神经病学 | 15384篇 |
特种医学 | 10102篇 |
外国民族医学 | 131篇 |
外科学 | 39793篇 |
综合类 | 42854篇 |
预防医学 | 11262篇 |
眼科学 | 2347篇 |
药学 | 28372篇 |
85篇 | |
中国医学 | 6938篇 |
肿瘤学 | 43790篇 |
出版年
2024年 | 222篇 |
2023年 | 3749篇 |
2022年 | 5948篇 |
2021年 | 9220篇 |
2020年 | 9587篇 |
2019年 | 8304篇 |
2018年 | 7449篇 |
2017年 | 8644篇 |
2016年 | 8922篇 |
2015年 | 9610篇 |
2014年 | 16420篇 |
2013年 | 17108篇 |
2012年 | 16335篇 |
2011年 | 18516篇 |
2010年 | 15438篇 |
2009年 | 15101篇 |
2008年 | 15138篇 |
2007年 | 15509篇 |
2006年 | 14278篇 |
2005年 | 13082篇 |
2004年 | 11017篇 |
2003年 | 9501篇 |
2002年 | 7824篇 |
2001年 | 6939篇 |
2000年 | 5938篇 |
1999年 | 4817篇 |
1998年 | 4081篇 |
1997年 | 3568篇 |
1996年 | 2753篇 |
1995年 | 2719篇 |
1994年 | 2408篇 |
1993年 | 1909篇 |
1992年 | 1689篇 |
1991年 | 1495篇 |
1990年 | 1286篇 |
1989年 | 1134篇 |
1988年 | 1052篇 |
1987年 | 953篇 |
1986年 | 850篇 |
1985年 | 1245篇 |
1984年 | 1227篇 |
1983年 | 800篇 |
1982年 | 942篇 |
1981年 | 789篇 |
1980年 | 668篇 |
1979年 | 578篇 |
1978年 | 486篇 |
1977年 | 334篇 |
1976年 | 294篇 |
1975年 | 219篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
3.
4.
5.
目的探讨肺癌患者化疗后的癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和鳞状上皮细胞癌抗原(SCC-Ag)表达变化。方法选取2017年5月至2020年2月间南京市六合区人民医院收治的100例肺癌患者,将这些患者作为肺癌组,另随机选取同期100例健康体检人员作为健康组。统计分析两组人员化疗前的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗成功患者化疗前后的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗失败患者化疗前后的血清NSE、CEA、SCC-Ag表达水平。结果肺癌组患者化疗前的血清NSE、CEA和SCC-Ag表达水平均高于健康组,差异均有统计学意义(均P <0.05)。肺癌组化疗成功患者化疗后的血清NSE、CEA和SCC-Ag表达水平均低于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。肺癌组化疗失败患者化疗后的血清NSE、CEA、SCC-Ag表达水平均高于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。结论对肺癌患者的NSE、CEA、SCC-Ag表达水平进行检测能够将化疗效果有效反映出来,进而有效指导临床的下一步治疗工作,从而有效改善患者预后。 相似文献
6.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
7.
8.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
9.
10.
Qing-Yang Que Lin-Cheng Zhang Jia-Qi Bao Sun-Bin Ling Xiao Xu 《World journal of gastrointestinal surgery》2022,14(5):397-408
Over the last 40 years, the incidence and prevalence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have continued to increase. Compared to other epithelial neoplasms in the same organ, GEP-NENs exhibit indolent biological behavior, resulting in more chances to undergo surgery. However, the role of surgery in high-grade or advanced GEP-NENs is still controversial. Surgery is associated with survival improvement of well-differentiated high-grade GEP-NENs, whereas poorly differentiated GEP-NENs that may benefit from resection require careful selection based on Ki67 and other tissue bio markers. Additionally, surgery also plays an important role in locally advanced and metastatic disease. For locally advanced GEP-NENs, isolated major vascular involvement is no longer an absolute contraindication. In the setting of metastatic GEP-NENs, radical intended surgery is recommended for patients with low-grade and resectable metastases. For unresectable metastatic disease, a variety of surgical approaches, including cytoreduction of liver metastasis, liver transplantation, and surgery after neoadjuvant treatment, show survival benefits. Primary tumor resection in GEP-NENs with unresectable metastatic disease is associated with symptom control, prolonged survival, and improved sensitivity toward systemic therapies. Although there is no established neoadjuvant or adjuvant strategy, increasing attention has been given to this emerging research area. Some studies have reported that neoadjuvant therapy effectively reduces tumor burden, improves the effectiveness of subsequent surgery, and decreases surgical complications. 相似文献